(BUSINESS WIRE)--MabSpace Biosciences announced today that the first subject has been dosed in a Phase 1 clinical study of MSB2311, for the treatment of advanced solid tumors.

HJB, an organization dedicated to expanding global access to important protein therapeutics, recently announced the establishment of its Center of Clinical Development (“the Center”) based in Boston.

(BUSINESS WIRE)--MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.

To benefit global patients by accelerating the design and manufacturing of innovative biologics that meet global standards.
HJB, an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility.

(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., today announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property.

HJB and G-CON Manufacturing today announced that the companies are working together on HJB’s state of the art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China.